Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel

Publisher:
Lippincott Williams & Wilkins
Publication Type:
Journal Article
Citation:
Anti-cancer Drugs, 2003, 14 (7), pp. 523 - 531
Issue Date:
2003-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2003000422OK.pdf545.72 kB
Adobe PDF
Small cell lung cancer (SCLC) responds to treatment with cisplatin and etoposide, but relapse is rapid and survival rates are low. Our aims were to determine the mechanisms of resistance and the potential for paclitaxel (Taxol) to overcome any drug or radiation resistance. To mimic clinical treatment, H69 SCLC cells, representative of the classic form of the disease, and H82 cells, with the phenotype of the more resistant variant disease, were treated intermittently with 100 ng/ml cisplatin or 500 ng/ml etoposide (approximate IC50 drug doses) to produce stable sublines. Drug and radiation resistance were determined using the MTT assay.
Please use this identifier to cite or link to this item: